ASX Announcement **30 April 2026**

Quarterly Activities Report
For The Period Ended 31 March 2026

Highlights:

- **Onboarding of all Clinical Sites for Pivotal FDA Study Completed:** BlinkLab successfully completed onboarding of its full U.S. clinical network of 10 leading autism centres where its FDA 510(k) Pivotal trial will be conducted.

- **First Participant Enrolled in FDA 510(k) Pivotal Validation:** BlinkLab has enrolled and successfully completed testing of the first participant, marking the commencement of its validation program for its autism diagnostic aid. The pivotal study will enroll ~528 children leveraging a geographically diverse and clinically rigorous network to generate registrational-grade evidence for FDA submission. Trial completion is anticipated for Q4 2026.

- **Launch of Nationwide Autism Screening Program in Morocco:** Government-led nationwide rollout for autism screening in Morocco positions BlinkLab as a leader in deployment of a scalable platform for screening of large populations.

- **Rapid Expansion of Clinical, Scientific and KOL Influence in the U.S.:** BlinkLab strengthened its position within the global autism research ecosystem through a combination of a peer-reviewed publication, strategic partnership with the SHANK2 Autism Foundation and participation in the Simons Foundation Autism Research Initiative (SFARI), reinforcing the Company's growing role in shaping next-generation diagnostic frameworks and clinical science.

- **Post-Reporting Period Successfully completed a A$17.5M placement to institutional and sophisticated investors.** Funds raised will be used to complete the FDA validation trial for autism, support product registration in the US and Europe, and launch a second clinical programme targeting ADHD.

BlinkLab Limited (ASX:BB1) ("BlinkLab", or the "Company"), a leading digital healthcare company focused on AI-powered diagnostics, is pleased to provide Quarterly Activities Report and Appendix 4C for the period ended 31 March 2026 (the "Quarter" or the "Reporting Period").

Commenting on the Quarter, Managing Director, CEO, and Co-Founder, Dr Henk-Jan Boele, stated:
"This Quarter is particularly meaningful for BlinkLab as it marks the two-year anniversary since our IPO and listing on the ASX. What has been achieved in that time is the result of an extraordinary amount of work from our team, the board, our clinical partners, and our supporters. We have moved

from early-stage development into a position where we are executing a pivotal regulatory study, engaging with the FDA, leading institutions globally, and even with governments. As a company we started as a 'simple' technology developer, two years later we are literally shaping the future of clinical decision-making in children with autism globally.

We look forward to upcoming study readouts that will highlight opportunities for BlinkLab beyond pediatric autism, particularly in additional clinical domains. Key among these are the European ADHD study with Mental Care Group and the adult autism program with the University of Amsterdam, which we believe will further demonstrate the breadth and scalability of our approach."

Operational Overview

FDA 510(k) Validation Program Study: From Network Completion to First Patient Testing

The March Quarter marked a defining transition for BlinkLab from preparation to execution of its U.S. FDA 510(k) pathway.

During the quarter the Company announced it had completed the onboarding of its full network of 10 leading U.S. clinical sites for its FDA validation trial, after announcing engagements with Drexel University on 12 February 2026 and the University of Arkansas on 16 March 2026. This was followed by the formal commencement of the pivotal validation program, when the company announced on the 24th of March that the first participant had been enrolled and had completed testing. In alignment with FDA expectations[1] and in collaboration with their global CRO, the study started with a dedicated usability phase. This phase was designed to ensure that clinicians and caregivers can safely and effectively use the BlinkLab platform in real-world settings, including correct operation of the system and appropriate interpretation of outputs. Execution of the study is being led by a global CRO, ensuring adherence to FDA-aligned protocols, data quality, and regulatory standards.

Importantly, the study builds on strong prior pilot data (n=485) announced in the previous reporting period,[2] where BlinkLab achieved 83.7% sensitivity and 84.7% specificity relative to gold-standard clinical assessments, significantly exceeding FDA-agreed thresholds (>65% / >65%), providing confidence in the likelihood of successful pivotal outcomes.

With recruitment expected to complete within approximately eight months, BlinkLab remains on track for FDA 510(k) submission by the end of CY2026, representing a major value inflection point for the Company as it progresses toward regulatory approval and commercialisation.

Beyond regulatory objectives, this clinical network also establishes deep relationships with leading U.S. autism centres and key opinion leaders, which upon success are expected to play a critical role in post-clearance adoption, guideline inclusion, and reimbursement pathways.

[1] https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-882/subpart-B/section-882.1491

[2] ASX Announcement (22 October 2025) – *"Pilot Study Confirms High Diagnostic Accuracy and Readiness for FDA Trial"*

Morocco National Program: First Large-Scale Government-led Deployment of Digital Autism Screening Platform

During the Quarter, BlinkLab announced the Dx1 platform had been chosen to support The Kingdom of Morocco's nationwide, government-funded autism screening initiative. This agreement represents the first time a digital diagnostic platform has been deployed at a national healthcare system level for autism screening and diagnosis. This initiative demonstrates, in a real-world setting, BlinkLab's ability to integrate the platform seamlessly into a coordinated, multi-ministry public healthcare framework and operate at population scale and across geographies.

BlinkLab's platform has been purpose-built for scalability, leveraging smartphone-based delivery, automated data capture, and AI-driven analysis to enable consistent, standardised assessments across thousands of decentralised care settings. This architecture is what makes national-level implementation not only possible, but practical.

Morocco provides a unique proof point of this capability, where more than 400,000 people are affected by autism across the nation. With approximately 600,000 children born annually and a nationwide screening program commencing from 18 months of age, BlinkLab's technology is being deployed across a broad network of primary care and specialised centres, supported entirely by government funding.

Strategically, this positions BlinkLab as a first mover in establishing a new paradigm for population-scale neurodevelopmental screening; one where digital, objective, and accessible tools can address longstanding challenges such as specialist shortages, long waitlists, and variability in clinical assessment.

Importantly, this is not only a deployment milestone but a practical validation of the Company's platform design philosophy. The ability to operate at this level reflects years of deliberate development that has been focused on usability, scalability, and real-world clinical integration; the capabilities that are increasingly critical for adoption by regulators, payers, and national healthcare systems.

In parallel, the program is expected to generate one of the largest standardised datasets in autism screening globally, further strengthening BlinkLab's dataset and supporting ongoing improvements in model performance and clinical utility for the platform.

Taken together, the nationwide screening initiative in Morocco reinforces BlinkLab's positioning as a diagnostic company, as well as a provider of scalable infrastructure for next-generation healthcare systems, with the potential to become a point of reference for replicating similar government-led deployments across other regions.

Growing U.S. Clinical Influence and Scientific Leadership

During the Quarter, BlinkLab significantly strengthened its position within the U.S. and global autism research ecosystem, advancing from a technology developer to an increasingly recognised

contributor to clinical science and future diagnostic frameworks. This was underpinned by three key developments: a peer-reviewed publication in *Autism Research*, a strategic partnership with the SHANK2 Autism Foundation, and participation in the Simons Foundation Autism Research Initiative (SFARI).

The peer-reviewed research publication, titled *"Neurobehavioral Assessment of Sensorimotor Function in Autism Using Smartphone Technology",*[3] provides independent scientific validation of BlinkLab's neurometric approach, demonstrating the ability to capture objective, quantifiable behavioural and sensorimotor signatures associated with autism. Importantly, this type of validation is a critical prerequisite for regulatory acceptance, clinical adoption, and long-term reimbursement pathways.

In parallel, the SHANK2 collaboration introduces BlinkLab into the rapidly emerging field of precision neurodevelopmental medicine, where genetically defined patient populations are increasingly used to develop targeted therapies. Access to these cohorts enables the Company to validate its technology in biologically homogeneous populations, which is expected to improve signal detection, accelerate biomarker development, and position BlinkLab as a potential provider of digital endpoints for future clinical trials.

Complementing these developments for the Company's contributions to research, BlinkLab's invitation to present at the Simons Foundation Autism Research Initiative (SFARI) places the Company directly within one of the most influential global networks of autism researchers and clinicians. Engagement at this level is a recognition of scientific credibility and a critical step in influencing how emerging technologies are evaluated, adopted, and ultimately embedded into clinical practice.

Taken together, these developments materially strengthen BlinkLab's strategic position in the U.S. market. While the Company continues to execute its FDA pivotal study, it is simultaneously building the scientific credibility, clinical relationships, and key opinion leader support required to drive adoption assuming regulatory clearance; an approach that is expected to significantly de-risk commercialisation and accelerate uptake in clinical settings.

Post-Reporting Period Capital Raise Supports Next Phase of Growth

Subsequent to the Reporting Period, the Company successfully completed an oversubscribed A$17.7 million capital raise and placement of shares to sophisticated, institutional and professional investors. The placement represents a significant milestone for BlinkLab and positions the Company strongly as it enters a critical phase of execution.

This capital enables the Company to simultaneously advance its U.S. FDA pivotal study, accelerate European regulatory activities, and expand into the large and complementary ADHD market, while ensuring it remains well-capitalised heading into early commercialisation. Importantly, the strong support from high-quality institutional investors reinforces confidence in BlinkLab's strategy and long-term opportunity.

[3] https://onlinelibrary.wiley.com/doi/epdf/10.1002/aur.70166

Financial Summary

Net cash used for operations for the Quarter ended 31 March 2026 was A$1.036 million, including the receipt of the R&D Tax Incentive refund of A$822,205 that was announced 8 January 2026.

Payments to related parties during the current quarter was ~$184,000 and relate to Director fees, salaries and superannuation.

Expenditure during the Quarter primarily related to research and development activities associated with the U.S. autism diagnostic program, regulatory preparation, support for European ADHD clinical study and ongoing corporate costs.

The Company's cash balance as at 31 March 2026 was A$4.319 million, which does not include the $17.7million capital raising (before costs) that was completed after the quarter end, on 16 April 2026.

This announcement has been approved by the Board of Directors.

For further information please contact:

Dr Henk-Jan Boele
Managing Director and CEO
henkjan@blinklab.org
+31 (0) 611 132 247

Brian Leedman
Non-Executive Chairman
brian@blinklab.org
+61 (0) 412 281 780

About BlinkLab Limited (ASX:BB1)

BlinkLab Limited was founded by neuroscientists at Princeton University and is developing a smartphone-based diagnostic platform for autism. Its most advanced product, BlinkLab Dx1, is an autism diagnostic aid for clinicians that leverages smartphones, artificial intelligence, and machine learning to capture objective, reflex-based measures, supporting earlier and more accurate autism identification. This enables timely intervention during critical periods of brain development. BlinkLab is led by an experienced management team and Board with deep expertise in digital healthcare, computer vision, and AI, supported by a Scientific Advisory Board of leading experts in autism and brain development.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
BlinkLab Limited	
ABN	**Quarter ended ("current quarter")**
53 652 901 703	31 March 2026

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (9 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	-	-
1.2	Payments for		
	(a) research and development	(1,469)	(4,335)
	(b) product manufacturing and operating costs	-	-
	(c) advertising and marketing	(174)	(418)
	(d) leased assets	-	-
	(e) staff costs	(70)	(169)
	(f) administration and corporate costs	(195)	(607)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	50	212
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	822	822
1.8	Other (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	**(1,036)**	**(4,495)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(43)	(117)
	(d) investments	-	-
	(e) intellectual property	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (9 months) $A'000
	(f) other non-current assets	(69)	(117)
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**(112)**	**(234)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	210
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	304
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	(7)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Payment of lease liability	(38)	(165)
3.10	**Net cash from / (used in) financing activities**	**(38)**	**342**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	5,509	8,711
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,036)	(4,495)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(112)	(234)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (9 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(38)	342
4.5	Effect of movement in exchange rates on cash held	(4)	(5)
4.6	**Cash and cash equivalents at end of period**	**4,319**	**4,319**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	2,789	2,509
5.2	Call deposits	1,530	3,000
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**4,319**	**5,509**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	(184)
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**		

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(1,036)
8.2	Cash and cash equivalents at quarter end (item 4.6)	4,319
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	4,319
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	**4.17**

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 30 April 2026

Authorised by: The Board of BlinkLab Limited

(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.